## Clinical Context This patient has symptomatic, recurrent AVNRT (4 episodes in 6 months) with documented electrophysiological diagnosis. The high frequency and symptom burden warrant definitive therapy rather than conservative management. ## Management Algorithm for Recurrent SVT ```mermaid flowchart TD A["Recurrent SVT with EP diagnosis"]:::outcome --> B{"Frequency & symptom burden?"}:::decision B -->|"Rare, minimally symptomatic"| C["Conservative: PRN adenosine, beta-blocker"]:::action B -->|"Frequent, highly symptomatic"| D["Radiofrequency catheter ablation"]:::action D --> E["Cure rate 95-99% for AVNRT"]:::outcome C --> F["Prophylactic antiarrhythmic if breakthrough"]:::action ``` ## Why Radiofrequency Catheter Ablation is Optimal **Key Point:** Radiofrequency catheter ablation (RFCA) is the definitive treatment for recurrent, symptomatic AVNRT and offers: - Cure rate of 95–99% - Elimination of need for long-term antiarrhythmic therapy - Excellent safety profile with low complication rates (<1%) - Improved quality of life **High-Yield:** Indications for RFCA in SVT: 1. Frequent, symptomatic episodes (≥2–3 per month or significant lifestyle impact) 2. Patient preference for definitive therapy 3. Failure or intolerance of antiarrhythmic drugs 4. Occupational constraints (pilots, drivers, etc.) 5. Documented EP diagnosis (as in this case) ## Comparison: Medical vs. Interventional Management | Aspect | Beta-Blocker (Medical) | RFCA (Interventional) | |--------|------------------------|----------------------| | **Cure rate** | 0% (suppression only) | 95–99% | | **Long-term therapy** | Lifelong required | Single procedure | | **Side effects** | Fatigue, bradycardia, sexual dysfunction | Rare (<1% complications) | | **Cost (long-term)** | Higher due to chronic medication | Lower after initial procedure | | **Quality of life** | Restricted by breakthrough episodes | Unrestricted post-ablation | | **Indication in this case** | Inadequate for 4 episodes/6 months | Ideal choice | **Clinical Pearl:** AVNRT is the most common form of SVT (~60% of cases) and is highly amenable to catheter ablation because the reentrant circuit is confined to the AV nodal region. The slow pathway (which perpetuates the arrhythmia) can be selectively ablated with excellent success and minimal risk of complete heart block. ## Why NOT Beta-Blocker Monotherapy While beta-blockers are appropriate for: - Rare, minimally symptomatic SVT - First-line prophylaxis in patients declining ablation They are inadequate here because: - The patient has 4 episodes in 6 months (frequent) - Beta-blockers suppress but do not cure the arrhythmia - The patient has already undergone EP study, indicating a desire for definitive management - Long-term side effects (fatigue, sexual dysfunction) are avoidable with ablation ## Why NOT Flecainide Flecainide is a class IC antiarrhythmic and is: - Not first-line for SVT (adenosine and beta-blockers are) - Reserved for patients who decline ablation or have contraindications - Associated with proarrhythmic effects in certain populations - Unnecessary when curative ablation is available ## Why NOT Immediate DC Cardioversion DC cardioversion is: - An acute management tool for hemodynamically unstable SVT - Not appropriate for a stable outpatient in a clinic setting - Not a long-term solution (does not prevent recurrence) [cite:Harrison 21e Ch 235]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.